Press Releases
Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately-Severe Acute Pain
NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion NTM-001 has the Potential to Deliver Opioid-Level Pain Relief, Without Analgesic Gaps, and Reduce or Eliminate the Need for Opioids Phase 3...
Neumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021
Nominated for Most Successful Early-Phase Research (Morristown, NJ - September 20, 2021) – The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an...
Neumentum to Participate in the UBS Biotechnology Private Company Symposium
MORRISTOWN, NJ, September 15, 2021– Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer and co-founder of Neumentum, and Dr. Joseph Pergolizzi,...
Neumentum Presents Latest Data on NTM-006, a Novel Non-Opioid, Non-NSAID Analgesic Drug Candidate, at PAINWeek 2021
Data Predicts NTM-006 Efficacy in a Variety of Chronic Pain Conditions MORRISTOWN, NJ, September 9, 2021– Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced data on NTM-006, the company’s...
Neumentum to Participate in Upcoming January Virtual Investor Conferences
Neumentum to Participate in Upcoming January Virtual Investor Conferences MORRISTOWN, NJ, January 5, 2021 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief...
Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition
Results from evaluation of novel non-opioid analgesic NTM-001, under development for post-surgical pain, support pathway to potential Phase 3 pivotal trials in 2021 MORRISTOWN, NJ, December 8, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming...
Neumentum to Participate in the Jefferies Virtual London Healthcare Conference
MORRISTOWN, NJ, November 5, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties MORRISTOWN, NJ, October 21, 2020 – Neumentum Inc., a pharmaceutical company dedicated to...
Neumentum to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
MORRISTOWN, NJ, September 10, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020
MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...
